AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26186135 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary inorganic arsenic plus methylated species (∑As) (µg/L) during pregnancy
Number of subjects: 1100
Study 26186135 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased urinary ∑As
Number of subjects: 1100
Study 26186135 — intervention group
Group type: COMPARATOR
Intervention: Non-seroconverting women (controls)
Number of subjects: 1100
Study 26186299 — intervention group
Group type: EXPERIMENTAL
Intervention: AIP mutation carriers screening
Number of subjects: 620
Study 26186299 — intervention group
Group type: EXPERIMENTAL
Intervention: AIP mutation carriers with truncating AIP mutations
Number of subjects: 620
Study 26186299 — intervention group
Group type: EXPERIMENTAL
Intervention: AIP mutation carriers
Number of subjects: 620
Study 26186299 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical screening of AIP mutation carriers
Number of subjects: 620
Study 26186432 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD overall group
Number of subjects: 157
Study 26186432 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD severity subgroups
Number of subjects: 157
Study 26186432 — intervention group
Group type: COMPARATOR
Intervention: Nondepressed group
Number of subjects: 157
Study 26186440 — intervention group
Group type: EXPERIMENTAL
Intervention: ART plus low doses of IL-2
Number of subjects: 12
Study 26186440 — intervention group
Group type: COMPARATOR
Intervention: ART alone
Number of subjects: 12
Study 26186440 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 group
Number of subjects: 12
Study 26186440 — intervention group
Group type: COMPARATOR
Intervention: STI group
Number of subjects: 12
Study 26186556 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy using docetaxel, cisplatin, and fluorouracil (TPF)
Number of subjects: 40
Study 26187031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir (90 mg) and sofosbuvir (400 mg) once daily for 12 weeks
Number of subjects: 21
Study 26187031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir and sofosbuvir treatment
Number of subjects: 21
Study 26187290 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular revascularization (ER)
Number of subjects: 1200
Study 26187290 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass surgery (BS)
Number of subjects: 1200
Study 26187290 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral/profundal artery patchplasty (FAP)
Number of subjects: 1200
Study 26187290 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 1200
Study 26187290 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary amputation
Number of subjects: 1200
Study 26187300 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa (150 μg single injection for 7 days, followed by daily recombinant FSH/hMG)
Number of subjects: 176
Study 26187510 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y-clivatuzumab tetraxetan plus low-dose gemcitabine (Arm A)
Number of subjects: 58
Study 26187510 — intervention group
Group type: COMPARATOR
Intervention: (90)Y-clivatuzumab tetraxetan alone (Arm B)
Number of subjects: 58
Study 26187603 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonconvulsive electrotherapy (NET)
Number of subjects: 13
Study 26187751 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 (2 cycles)
Number of subjects: 259
Study 26187751 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 (4 cycles)
Number of subjects: 259
Study 26187751 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 (6 cycles)
Number of subjects: 259
Study 26187751 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiation only (group 1)
Number of subjects: 259
Study 26187751 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery-related complications
Number of subjects: 259
Study 26187864 — intervention group
Group type: EXPERIMENTAL
Intervention: MUD transplantation with TCRαβ/CD19 depletion
Number of subjects: 37
Study 26187864 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRD transplantation with TCRαβ/CD19 depletion
Number of subjects: 37
Study 26187864 — intervention group
Group type: EXPERIMENTAL
Intervention: MUD and MMRD transplantation with TCRαβ/CD19 depletion
Number of subjects: 37
Study 26188212 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol efflux capacity (CEC)
Number of subjects: 101
Study 26188235 — intervention group
Group type: EXPERIMENTAL
Intervention: GNAS mutation analysis in adrenal tissue
Number of subjects: 1
Study 26188235 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical findings in MAS
Number of subjects: 1
Study 26189058 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib + Radiotherapy (RT)
Number of subjects: 18
Study 26189353 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandage soft contact lenses (BSCLs)
Number of subjects: 19
Study 26189885 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleepers (≤6 h)
Number of subjects: 11888
Study 26189885 — intervention group
Group type: EXPERIMENTAL
Intervention: Long sleepers (≥9 h)
Number of subjects: 11888
Study 26189885 — intervention group
Group type: EXPERIMENTAL
Intervention: Not consuming a snack or meal within 3 h before bedtime
Number of subjects: 11888
Study 26189885 — intervention group
Group type: COMPARATOR
Intervention: Long sleepers
Number of subjects: 11888
Study 26189885 — intervention group
Group type: EXPERIMENTAL
Intervention: AHEI-2010 score
Number of subjects: 11888
Study 26189934 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 antibodies (e.g., nivolumab)
Number of subjects: 0
Study 26189934 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PD-1 pathway blockade with other anticancer agents
Number of subjects: 0
Study 26190488 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGFR1-derived peptide vaccination in combination with gemcitabine
Number of subjects: 4
Study 26190488 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone (implied control)
Number of subjects: 4
Study 26190562 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol < 300 mg
Number of subjects: 1732
Study 26190562 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg
Number of subjects: 1732
Study 26190562 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol > 300 mg
Number of subjects: 1732
Study 26191050 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% Chlorhexidine mouthwash application
Number of subjects: 15
Study 26191050 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential Oils (EO) mouthwash application
Number of subjects: 15
Study 26191050 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% Chlorhexidine immersion
Number of subjects: 15
Study 26191050 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential Oils (EO) immersion
Number of subjects: 15
Study 26191050 — intervention group
Group type: EXPERIMENTAL
Intervention: Active mouthwash application
Number of subjects: 15
Study 26191050 — intervention group
Group type: COMPARATOR
Intervention: Passive immersion
Number of subjects: 15
Study 26193343 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 80
Study 26193887 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin levels
Number of subjects: 120
Study 26194453 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Foundations (FF) intervention
Number of subjects: 259
Study 26194453 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 259
Study 26194541 — intervention group
Group type: EXPERIMENTAL
Intervention: Baked milk oral immunotherapy (BM OIT) with a dose of 1.3 g/d BM protein, increased 50% monthly under medical supervision.
Number of subjects: 15
Study 26194541 — intervention group
Group type: EXPERIMENTAL
Intervention: Baked milk oral immunotherapy (BM OIT)
Number of subjects: 15
Study 26194684 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC tracking
Number of subjects: 15
Study 26194684 — intervention group
Group type: COMPARATOR
Intervention: without MLC tracking
Number of subjects: 15
Study 26194896 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior parasagittal in-plane ultrasound-guided infraclavicular brachial plexus block
Number of subjects: 18
Study 26194896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadaveric dissection
Number of subjects: 18
Study 26194996 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural respiratory drive measured using EMGpara
Number of subjects: 120
Study 26194996 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 120
Study 26194996 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month admission frequency
Number of subjects: 120
Study 26195015 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori infection in ART-naive HIV-positive patients
Number of subjects: 457
Study 26195015 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori infection in HIV-negative individuals
Number of subjects: 457
Study 26195184 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg/day for 2 weeks, followed by 1.2 mg/day, in addition to metformin
Number of subjects: 29
Study 26195184 — intervention group
Group type: COMPARATOR
Intervention: Control group (T2DM without NAFLD)
Number of subjects: 29
Study 26195184 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study 26195220 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial nitric oxide synthase-transfected endothelial progenitor cells (7 to 50 million cells, divided into 3 doses on consecutive days)
Number of subjects: 7
Study 26195220 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial nitric oxide synthase-transfected endothelial progenitor cells
Number of subjects: 7
Study 26195674 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid coverage (gaining Medicaid)
Number of subjects: 34849
Study 26195674 — intervention group
Group type: COMPARATOR
Intervention: Not selected for Medicaid
Number of subjects: 34849
Study 26195720 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.8 mg/kg) every 3 weeks for a maximum of sixteen doses
Number of subjects: 32
Study 26195720 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 32
Study 26196195 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonacog alfa treatment
Number of subjects: 412
Study 26196225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan (5 or 10 mg once daily)
Number of subjects: 0
Study 26196225 — intervention group
Group type: COMPARATOR
Intervention: Ambrisentan and tadalafil (upfront initial combination therapy)
Number of subjects: 0
Study 26196225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Number of subjects: 0
Study 26196233 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH (Antimüllerian hormone)
Number of subjects: 487
Study 26196233 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and AMH
Number of subjects: 487
Study 26196665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir and sofosbuvir for 12 weeks
Number of subjects: 335
Study 26197243 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-restricted treatment (hypocaloric diet)
Number of subjects: 96
Study 26197243 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline dietary total antioxidant capacity (TAC)
Number of subjects: 96
Study 26197404 — intervention group
Group type: EXPERIMENTAL
Intervention: VAR protocol (prospective, longitudinal, multicenter study)
Number of subjects: 60
Study 26197404 — intervention group
Group type: EXPERIMENTAL
Intervention: Echo analysis and genetic testing
Number of subjects: 60
Study 26197982 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher level of neighborhood social capital (informal socializing)
Number of subjects: 12568
Study 26197982 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher level of neighborhood social capital (voting turnout)
Number of subjects: 12568
Study 26197982 — intervention group
Group type: COMPARATOR
Intervention: Individual socioeconomic position and neighborhood deprivation
Number of subjects: 12568
Study 26198286 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-AKI
Number of subjects: 9512
Study 26199039 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridaforolimus 20 mg daily (5 days/week) + MK-0752 1800 mg weekly
Number of subjects: 28
Study 26199039 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridaforolimus 30 mg daily (5 days/week) + MK-0752 1800 mg weekly
Number of subjects: 28
Study 26199039 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ridaforolimus and MK-0752
Number of subjects: 28
Study 26199039 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum tolerated dose (MTD)
Number of subjects: 28
Study 26199039 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 28
Study 26199392 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential high-dose chemotherapy (HDC) with bevacizumab preceding GemDMC (cycle 1) and ICE (cycle 2)
Number of subjects: 43
Study 26199453 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) 40 mg every other week or monthly
Number of subjects: 846
Study 26200040 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium aluminosilicate antidiarrheal (CASAD)
Number of subjects: 10
Study 26200040 — intervention group
Group type: EXPERIMENTAL
Intervention: CASAD
Number of subjects: 10
Study 26200236 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal pre-pregnancy body mass index (ppBMI)
Number of subjects: 976
Study 26200236 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-pregnancy gestational weight gain (GWG)
Number of subjects: 976
Study 26200236 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal pre-pregnancy body mass index (ppBMI) and mid-pregnancy GWG
Number of subjects: 976
Study 26201019 — intervention group
Group type: EXPERIMENTAL
Intervention: CoroMarker (lncRNA AC100865.1)
Number of subjects: 221
Study 26201460 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab injections (3 injections)
Number of subjects: 1333
Study 26201818 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Number of subjects: 40
Study 26201818 — intervention group
Group type: COMPARATOR
Intervention: Morbidly obese patients
Number of subjects: 40
Study 26201818 — intervention group
Group type: COMPARATOR
Intervention: Nonobese patients
Number of subjects: 40
Study 26201818 — intervention group
Group type: COMPARATOR
Intervention: Gallbladder emptying
Number of subjects: 40
Study 26201817 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg pyridoxine hydrochloric acid/d for 28 days
Number of subjects: 10
Study 26202132 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum apoE
Number of subjects: 84
Study 26202132 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum high-density lipoprotein cholesterol
Number of subjects: 84
Study 26202132 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor age
Number of subjects: 84
Study 26202442 — intervention group
Group type: EXPERIMENTAL
Intervention: 23G vitrectomy
Number of subjects: 347
Study 26202442 — intervention group
Group type: EXPERIMENTAL
Intervention: 25G vitrectomy
Number of subjects: 347
Study 26202442 — intervention group
Group type: COMPARATOR
Intervention: 20G vitrectomy
Number of subjects: 347
Study 26202647 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training incorporated into Pulmonary Rehabilitation (PR) three times a week
Number of subjects: 19
Study 26202647 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care professionals (HCPs) training on balance training principles and practical application
Number of subjects: 19
Study 26202768 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc 150 mg twice daily with a protease inhibitor
Number of subjects: 18
Study 26202768 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg twice daily without a protease inhibitor
Number of subjects: 18
Study 26202768 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative regimen
Number of subjects: 18
Study 26202768 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall maraviroc exposure
Number of subjects: 18
Study 26202768 — intervention group
Group type: EXPERIMENTAL
Intervention: Ctrough
Number of subjects: 18
Study 26202768 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral load close to delivery
Number of subjects: 18
Study 26202768 — intervention group
Group type: EXPERIMENTAL
Intervention: Children tested for HIV
Number of subjects: 18
Study 26202922 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 1376
Study 26202922 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1376
Study 26202922 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clomiphene citrate and metformin
Number of subjects: 1376
Study 26202922 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 1376
Study 26202922 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking status
Number of subjects: 1376
Study 26203353 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy (GDFT) with arterial-based continuous stroke volume variation (SVV) monitoring
Number of subjects: 164
Study 26203353 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard fluid therapy)
Number of subjects: 164
Study 26203760 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted pterygium surgery using the DaVinci Si HD robotic Surgical System
Number of subjects: 1
Study 26203904 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Dietary Diversity Score (DDS)
Number of subjects: 886
Study 26203904 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal Source Foods (ASF) intake
Number of subjects: 886
Study 26203904 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-demographic factors affecting DDS
Number of subjects: 886
Study 26203904 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences in ASF intake
Number of subjects: 886
Study 26205215 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (GBP)
Number of subjects: 52
Study 26205215 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 52
Study 26205215 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic multivitamin and mineral supplementation after GBP and SG
Number of subjects: 52
Study 26205445 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel and subsequent prasugrel loading dose
Number of subjects: 2023
Study 26205445 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel loading dose alone
Number of subjects: 2023
Study 26205955 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course neoadjuvant chemotherapy (NACT) followed by long-course chemoradiotherapy and definitive surgery, with a focus on the increase in circulating carbonic anhydrase IX (CAIX) levels above a threshold of 224 pg/ml after NACT.
Number of subjects: 0
Study 26205955 — intervention group
Group type: EXPERIMENTAL
Intervention: CAIX parameter ΔNACT (change in CAIX levels post-NACT).
Number of subjects: 0
Study 26206158 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic management patterns (AMPs) during hospitalization and post-discharge
Number of subjects: 12922
Study 26207061 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Empowerment Programme (PEP)
Number of subjects: 0
Study 26207614 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine, oxaliplatin, and irinotecan plus bevacizumab
Number of subjects: 53
Study 26208006 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic screening for rheumatic heart disease (RHD) using modified WHO criteria
Number of subjects: 1023
Study 26208006 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic screening for rheumatic heart disease (RHD) using WHF criteria
Number of subjects: 1023
Study 26208006 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic screening for congenital heart disease
Number of subjects: 1023
Study 26208217 — intervention group
Group type: COMPARATOR
Intervention: Obese mothers (n=64)
Number of subjects: 331
Study 26208217 — intervention group
Group type: COMPARATOR
Intervention: Overweight mothers (n=56)
Number of subjects: 331
Study 26208217 — intervention group
Group type: COMPARATOR
Intervention: Gestational diabetic mothers (n=79)
Number of subjects: 331
Study 26208217 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight controls (n=132)
Number of subjects: 331
Study 26208483 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA disruption assay (RDA) Zone 3
Number of subjects: 0
Study 26208483 — intervention group
Group type: COMPARATOR
Intervention: RNA disruption assay (RDA) Zone 1
Number of subjects: 0
Study 26208483 — intervention group
Group type: EXPERIMENTAL
Intervention: pCR responders in RDA Zone 3
Number of subjects: 0
Study 26208483 — intervention group
Group type: EXPERIMENTAL
Intervention: High tumor RNA disruption
Number of subjects: 0
Study 26208671 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure (HBP) measurement using telemedical data transmission
Number of subjects: 3102
Study 26208671 — intervention group
Group type: COMPARATOR
Intervention: Office Blood Pressure (OBP) measurement
Number of subjects: 3102
Study 26208671 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure (HBP) measurement indicating persistent hypertension
Number of subjects: 3102
Study 26208671 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure (HBP) measurement indicating white coat hypertension (WCH)
Number of subjects: 3102
Study 26208671 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure (HBP) measurement indicating masked hypertension (MH)
Number of subjects: 3102
Study 26208810 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium levels in adults with metabolic syndrome
Number of subjects: 5496
Study 26208810 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium levels in adults with metabolic syndrome in West Asia
Number of subjects: 5496
Study 26208810 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium levels in adults with metabolic syndrome in Latin America
Number of subjects: 5496
Study 26208810 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium levels in adults with metabolic syndrome in East Asia
Number of subjects: 5496
Study 26208810 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium levels in adults with metabolic syndrome in Europe/Oceania
Number of subjects: 5496
Study 26208810 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium levels in high-quality studies
Number of subjects: 5496